Potential partners are invited to explore collaboration opportunities with VUNO Med\u00ae-DeepBrain\u00ae, a highly accurate AI solution for research and clinical settings. <\/p>\n
MARLBOROUGH, Mass.<\/span><\/span>, June 17, 2024<\/span><\/span> \/PRNewswire\/ — VUNO<\/a>\u2014<\/span>acclaimed as a pioneer in AI-based medical solutions\u2014announced 3 upcoming poster presentations showcasing their latest brain analysis research at the Alzheimer’s Association International Conference (AAIC)<\/a>. Discover collaboration opportunities for improved monitoring and diagnosis of patients with Alzheimer’s Dementia and other neurological diseases. See poster presentations and live demos at AAIC booth exhibit #1411<\/a> from July 28<\/span>th to August 1<\/span>st<\/span> in Philadelphia, PA.<\/span><\/p>\n The poster presentations will feature VUNO Med\u00ae-DeepBrain\u00ae\u2014FDA-cleared in October 2023<\/span>, a highly accurate, fast atrophy and WMH measurement AI solution\u2014within the following topics:<\/p>\n Quantitative Analysis of Choroid Plexus Enlargement in Alzheimer’s Dementia: A Study of Automated Volumetric Technique <\/span> Automated Brain Volumetry Analysis for Differential Diagnosis of Frontotemporal Dementia Subtypes <\/span> Comparison of Intracranial Volume Adjustment Methods to Evaluate Brain Atrophy Severity in AD Continuum <\/span> <\/p>\n VUNO’s researchers and in-house<\/span> radiologist<\/span> will present research findings and address audience questions. \u00a0<\/p>\n “We aim to reduce neurodegenerative professionals’ workloads while providing advanced insights to support their practice goals,” said Yeha Lee, CEO of VUNO. “As part of the commercial U.S. launch of VUNO Med\u00ae-DeepBrain\u00ae in 2024, we are collaborating with leading medical providers<\/span>, researchers and institutions<\/span> to pilot our solution and to provide valuable, real-world feedback.”<\/p>\n Neurologists, dementia professionals and researchers attending AAIC can book a free demo<\/a> t<\/span>o learn more about VUNO Med\u00ae-DeepBrain\u00ae in advance of the show or stop by booth 1411<\/a> during<\/span> July 28-August 1<\/span>.<\/p>\n ABOUT VUNO VUNO innovates internationally recognized solutions with 100+ patents and 100+ publications. VUNO Med\u00ae-DeepBrain\u00ae is an atrophy and WMH measurement AI solution that boasts high accuracy and speed of analysis (1 minute).<\/p>\n For more information, visit VUNO.us<\/a>.<\/span><\/p>\n ABOUT AAIC Media Contact: us@vuno.co<\/a><\/span><\/p>","protected":false},"excerpt":{"rendered":" <\/p>\n Potential partners are invited to explore collaboration opportunities with VUNO Med\u00ae-DeepBrain\u00ae, a highly accurate AI solution for research and clinical settings. <\/p>\n MARLBOROUGH, Mass.<\/span><\/span>, June 17, 2024<\/span><\/span> \/PRNewswire\/ — VUNO<\/a>\u2014<\/span>acclaimed as a pioneer in AI-based medical solutions\u2014announced 3 upcoming poster presentations showcasing their latest brain analysis research at the Alzheimer’s Association International Conference (AAIC)<\/a>. Discover collaboration opportunities for improved monitoring and diagnosis of patients with Alzheimer’s Dementia and other neurological diseases. See poster presentations and live demos at AAIC booth exhibit #1411<\/a> from July 28<\/span>th to August 1<\/span>st<\/span> in Philadelphia, PA.<\/span><\/p>\n The poster presentations will feature VUNO Med\u00ae-DeepBrain\u00ae\u2014FDA-cleared in October 2023<\/span>, a highly accurate, fast atrophy and WMH measurement AI solution\u2014within the following topics:<\/p>\n Quantitative Analysis of Choroid Plexus Enlargement in Alzheimer’s Dementia: A Study of Automated Volumetric Technique <\/span> Automated Brain Volumetry Analysis for Differential Diagnosis of Frontotemporal Dementia Subtypes <\/span> Comparison of Intracranial Volume Adjustment Methods to Evaluate Brain Atrophy Severity in AD Continuum <\/span> <\/p>\n VUNO’s researchers and in-house<\/span> radiologist<\/span> will present research findings and address audience questions. \u00a0<\/p>\n “We aim to reduce neurodegenerative professionals’ workloads while providing advanced insights to support their practice goals,” said Yeha Lee, CEO of VUNO. “As part of the commercial U.S. launch of VUNO Med\u00ae-DeepBrain\u00ae in 2024, we are collaborating with leading medical providers<\/span>, researchers and institutions<\/span> to pilot our solution and to provide valuable, real-world feedback.”<\/p>\n Neurologists, dementia professionals and researchers attending AAIC can book a free demo<\/a> t<\/span>o learn more about VUNO Med\u00ae-DeepBrain\u00ae in advance of the show or stop by booth 1411<\/a> during<\/span> July 28-August 1<\/span>.<\/p>\n ABOUT VUNO VUNO innovates internationally recognized solutions with 100+ patents and 100+ publications. VUNO Med\u00ae-DeepBrain\u00ae is an atrophy and WMH measurement AI solution that boasts high accuracy and speed of analysis (1 minute).<\/p>\n For more information, visit VUNO.us<\/a>.<\/span><\/p>\n
Headquartered in South Korea<\/span> with their USA<\/span> Corporate office located in Marlborough, MA<\/span>, VUNO is a leading AI medical software company that develops deep learning-based AI medical solutions in medical imaging, biosignal, and digital pathology\u2013optimizing in-clinic and telehealth patient care with their portfolio of deep learning-based tools.<\/p>\n
The Alzheimer’s Association International Conference (AAIC)<\/a>\u00a0is the largest international meeting dedicated to advancing dementia science and clinical practice.<\/p>\n
Headquartered in South Korea<\/span> with their USA<\/span> Corporate office located in Marlborough, MA<\/span>, VUNO is a leading AI medical software company that develops deep learning-based AI medical solutions in medical imaging, biosignal, and digital pathology\u2013optimizing in-clinic and telehealth patient care with their portfolio of deep learning-based tools.<\/p>\n